Peptide Initiative

Dosing protocol · Immune

Nisin dosing & administration

FDA GRAS-approved lantibiotic (34 amino acids) produced by Lactococcus lactis with a dual antimicrobial mechanism — binds lipid II to block cell wall synthesis AND forms 2 nm transmembrane pores for rapid bacterial killing at MIC 0.5-4 μg/mL against gram-positive pathogens including MRSA and Listeria monocytogenes — the only antimicrobial peptide with over 50 years of documented safe human consumption

Suggested dose

10 – 50 mcg

Once or twice dailyFrequency
TopicalRoute
Ongoing/indefiniteCycle length

Dosing

How much Nisin do I take?

Topical

Topical: Applied onto the skin as a cream, gel, or lotion — it works mainly where you put it.

Bioavailability Local — acts mainly at the skin; little reaches the bloodstream.

  • 10-50 mcg/mL applied to the affected area

    Frequency
    Once or twice daily
    Duration
    Research protocol-dependent (typically 1-4 weeks)

    Topical antimicrobial concentration range used in wound-care and infection-control research . Investigational; not an approved human therapeutic route.

Timing

Best time to take

Take Nisin at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.

With food?

Nisin can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.

If stacking

Nisin should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

Adjusting your dose

Increase if

  • You've tolerated the current dose for the recommended period without significant side effects
  • Therapeutic goals haven't been met at the current dose level
  • Your healthcare provider recommends dose escalation based on your response
  • Lab work or clinical assessments support a higher dose

Decrease if

  • Side effects are bothersome or impacting daily life despite management strategies
  • You experience any signs of an adverse reaction
  • Lab results indicate the need for dose reduction
  • Your healthcare provider recommends a lower dose based on your response

Signs of right dose

  • Therapeutic goals being met with minimal side effects
  • Stable and consistent response to treatment
  • Lab values or clinical markers trending in the right direction
  • Good tolerance with manageable or absent side effects

Administration

How do I use Nisin?

Reconstitution

What you need

  • Nisin in its prescribed form
  • Clean, dry storage container
  • Measuring device if applicable (oral syringe, measuring cup)
  • Calendar or reminder app for dosing schedule

Injection

Route

Nisin is administered Oral (food-grade preservative, GRAS)—no injection required

Best sites

  • Not applicable—this is not an injectable formulation

Storage

Before reconstitution

Store Nisin in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

After reconstitution

Once reconstituted, Nisin should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs of degradation — discard the vial

  • Solution appears cloudy, discolored, or contains visible particles (should be clear)
  • Product has been exposed to temperatures outside the recommended storage range
  • Product has been frozen (unless specifically designed for freeze-thaw stability)
  • Expiration date has passed or reconstituted solution has exceeded its use-by date
  • Unusual odor, color change, or visible contamination

Sample daily schedule

  • As prescribed (once daily)

    As prescribed by your healthcare provider injection

    Site: Oral (food-grade preservative, GRAS)—rotate sites if applicable

    Maintain a consistent schedule for optimal results with Nisin. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.

Safety

Is Nisin safe?

Side effects

Commonly reported: No significant effects at dietary levels, Mild GI discomfort at research doses, Local irritation (topical use)

Less common: Milk protein allergic reaction, Gram-negative overgrowth

Serious side effects

  • No documented serious adverse effects

Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Nisin
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Nisin should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

Flagged pairings

  • Alkaline formulations (pH >7) — nisin activity and stability decrease significantly above neutral pH, with degradation accelerating at alkaline conditions — Use with caution—discuss with your healthcare provider.
  • Proteolytic enzymes (trypsin, chymotrypsin at high concentrations) — while lanthionine bridges provide some resistance, extensive proteolysis can reduce activity — Use with caution—discuss with your healthcare provider.
  • High-fat food matrices without emulsification — nisin may partition into fat phase, reducing aqueous concentration and antimicrobial activity — Use with caution—discuss with your healthcare provider.

Published research

What the studies show

  • Strong human trials (Phase 3 or FDA approved)
  • Not an FDA-approved drug. Nisin preparation is affirmed as GRAS (21 CFR 184.1538, 1988) only as a food antimicrobial, for example to inhibit Clostridium botulinum in pasteurized cheese spreads; therapeutic uses are investigational.
  1. New Insights into Nisin's Antibacterial Mechanism Revealed by Binding Studies with Synthetic Lipid II Analogues

    't Hart P, Oppedijk SF, Breukink E, et al. · 2016PubMed

    Nisin binds to bacterial lipid II through its pyrophosphate group, with the complete sugar unit required for tight binding and pore formation in bacterial membranes.

  2. The apoptotic impact of nisin as a potent bacteriocin on the colon cancer cells

    Ahmadi S, Ghollasi M, Hosseini HM · 2017PubMed

    Research (2016) on nisin contributes important scientific knowledge about its biological and pharmacological properties.

  3. Synergistic anticancer activity of antimicrobial peptide nisin and doxorubicin against breast cancer cells via modulation of membrane permeability

    Phetdee C, Naephrai S, Pradain M, Panporm Y, Ahmad U, Prangkio P · 2026PubMed

    PLoS One 2026;21(6):e0352312 (PMID 42335141). Nisin was cytotoxic to MCF-7 and MDA-MB-231 breast cancer cells (IC50 5-8 µM) with lower toxicity to normal cells, permeabilized membranes preferentially via anionic lipids, and acted synergistically with doxorubicin to enhance apoptosis.

  4. Combination therapy with nisin, urolithin B, and vincristine exhibits synergistic antiproliferative and pro-apoptotic effects against human lymphoma cells: evidence from proteomics

    Al-Khazaleh AK, Alsherbiny MA, Chang D, et al. · 2025PubMed

    Study (2014) elucidates the molecular mechanism of action and biological pathways by which nisin produces therapeutic effects.

  5. Nisin-biogel against Staphylococcus aureus isolates from diabetic foot infections (topical antimicrobial concentrations)

    Jesus C, Soares R, Cunha E, Grilo M, Tavares L, Oliveira M · 2021PubMed

    In vitro study of nisin (as a nisin-biogel) against Staphylococcus aureus isolated from diabetic foot wound infections. The mean nisin MIC against these wound isolates was approximately 22.5 ug/mL, with sub-inhibitory concentrations (~2.8-11.25 ug/mL) tested for effects on virulence-gene expression. This supports the ~10-50 ug/mL range used in topical/wound antimicrobial formulation work; it is in-vitro/formulation research, not an approved human therapeutic dose.

  6. Anticancer activity of cloned Nisin as an alternative therapy for MCF-7 breast cancer cell line

    Said Taha S, Abdulrahman ZFA, Othman RT (2023) · 2023DOI

    MTT assay reports nisin exhibits high and selective cytotoxicity against the MCF-7 breast cancer cell line with an IC50 value of 11.68 µg/ml (PMID 37807320). This is the source of the page's MCF-7 IC50 figure.

  7. 21 CFR 184.1538 — Nisin preparation (direct food substance affirmed as GRAS)

    U.S. Food and Drug Administration (Electronic Code of Federal Regulations) · 1988ecfr.gov

    Nisin preparation from Streptococcus lactis fermentation is affirmed as GRAS (53 FR 11250, 6 April 1988) for use as an antimicrobial to inhibit the outgrowth of Clostridium botulinum spores and toxin formation in pasteurized cheese spreads and process cheese spreads, at levels not exceeding good manufacturing practice. This is a food-ingredient status, not drug approval.

Head to head

Nisin compared

Want the full picture?

The complete Nisin research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.